Bio-Rad Laboratories Inc (BIO)

Interest coverage

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	-800,689	-138,444	-483,599	-204,999	-4,666,145	-7,802,795	-2,582,920	-213,620	5,450,550	8,569,990	5,235,930	5,327,770	4,931,957	4,551,705	2,531,870	2,055,642	2,284,525	543,937	1,229,781	800,369
Interest expense (ttm)	US$ in thousands	49,439	48,761	48,026	46,403	38,114	26,795	15,558	5,201	1,551	5,890	11,192	16,569	21,861	23,222	23,019	23,120	23,416	23,491	24,030	24,166
Interest coverage		-16.20	-2.84	-10.07	-4.42	-122.43	-291.20	-166.02	-41.07	3,514.22	1,455.01	467.83	321.55	225.61	196.01	109.99	88.91	97.56	23.16	51.18	33.12

December 31, 2023 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $-800,689K ÷ $49,439K
= -16.20

Bio-Rad Laboratories Inc. has consistently maintained a healthy interest coverage ratio over the quarters, indicating its ability to meet its interest obligations from its operating income. The declining trend in the interest coverage ratio from Q1 2023 to Q4 2023 may indicate a slight decrease in the company's ability to cover its interest expenses. However, the ratios remain well above 1, suggesting that Bio-Rad Laboratories Inc. is generating sufficient earnings to comfortably cover its interest payments. The remarkable interest coverage ratios seen in Q2 2022 and Q1 2022 indicate strong financial health and stability during those periods. Overall, it appears that Bio-Rad Laboratories Inc. has a strong financial position in terms of its ability to manage its interest expenses.